Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib vs Bevacizumab in First-Line Metastatic Colorectal Cancer
NCT00904839Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2009
- Primary completion
- Jan 2012
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 5
01
Overview
A Phase 2 trial of nintedanib intravenous solution in metastatic colorectal cancer (mCRC), sponsored by Boehringer Ingelheim. Started May 2009; status: completed.
02
Drugs
nintedanib intravenous solution
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00904839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00904839.